Corvallis, MT, United States of America

Michael J Munchhof

This inventor holds 4 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignee: Eli Lilly and Company. Active years: 2023-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael J Munchhof. Retrieved from https://idiyas.com/inventor/michael-j-munchhof

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 4 

% Patents Active = 100.0

 

Average Co-Inventor Count = 12.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2023-2024

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Michael J Munchhof: Innovator in RET Kinase Inhibitors

Introduction

Michael J Munchhof is a prominent inventor based in Corvallis, MT (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of RET kinase inhibitors. With a total of 4 patents to his name, Munchhof's work is instrumental in advancing treatments for RET-associated cancers.

Latest Patents

Munchhof's latest patents focus on innovative compounds that serve as RET kinase inhibitors. One of his notable patents discloses compounds of formula I, which are useful in treating RET-associated cancers. These compounds can be formulated into pharmaceutically acceptable salts and are accompanied by methods for their synthesis. Another patent provides formulations containing these compounds and outlines their application in treating diseases that can be addressed with RET kinase inhibitors.

Career Highlights

Michael J Munchhof is currently associated with Eli Lilly and Company, where he continues to push the boundaries of pharmaceutical research. His work has garnered attention for its potential to improve treatment options for patients suffering from RET-associated diseases.

Collaborations

Munchhof collaborates with talented professionals in his field, including Gabrielle R Kolakowski and Erin Danielle Anderson. Their combined expertise contributes to the innovative research and development efforts at Eli Lilly and Company.

Conclusion

Michael J Munchhof's contributions to the field of RET kinase inhibitors highlight his role as a key innovator in pharmaceutical research. His patents and ongoing work promise to enhance treatment options for patients with RET-associated cancers.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…